Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on November 10, 2022. The filing serves to announce the company's financial results for the three-month period ended September 30, 2022. AgeX is an emerging growth company incorporated in Delaware, with its common stock trading on the NYSE American under the symbol AGE.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1. Consequently, no specific financial metrics can be extracted from this document alone.
Material Changes
The filing does not provide specific data regarding material changes compared to prior periods. It references the press release (Exhibit 99.1) for the announcement of results but does not summarize the variances or trends within the text of the 8-K.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: Investors are directed to the "Risk Factors" section of AgeX's periodic reports filed with the SEC for additional factors that could cause actual results to differ materially from anticipated results.
- Management Commentary: No specific management commentary or outlook is provided in the body of this 8-K; the document acts solely as a conduit to the press release.
Important Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 10, 2022), as they are not listed in this summary document.
- Confirm the company name is AgeX Therapeutics, Inc., as the input metadata incorrectly referenced "Serina Therapeutics, Inc."
- Note that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Review the company's most recent periodic reports for detailed risk factors affecting future performance.